The global hot market for herpe vaccine in China is cold, and annual sales of $4.7 billion are in a stagnating position.

The GlaxoStick re-organizing herpe vaccine under the banner of Grynzo Schultz has achieved a global sales breakthrough of £3,558 million in 2025, amounting to approximately $4,705 million. For five years in a row, it has remained at the top of the world's global vaccine sales and has become an international blowout in the field of adult vaccines. However, this star product, which is powerful in overseas markets, has experienced clear land and water overflows in China, and sales have continued to decline. Herpes are an infectious skin disease caused by the herpes-and-herpe virus. More than 90% of the adult population sleeps with the virus. The global medical community has recognized vaccines as the most effective means to prevent herpes. Xin-ai has been more than 97% effective, but in China's market, despite being marketed in 2020, the price of full-scale vaccinations at a cost of approximately $3260 has slowed many consumers' expectations. In 2023, the country produced a live vaccine for herpe reduction, which fell to about $700, but still faces marketing difficulties. Industry sources have analysed that the root causes of the cold in China’s market are threefold obstacles: first, the lack of public awareness of herpe-related diseases, with 85.7% of the elderly not believing themselves to be ill; secondly, the high price, which exceeds the budget of many families; and thirdly, the medical payment system, which focuses on preventive treatment and requires full self-funding for vaccines. Together, these factors have led to a widespread problem in China with the international vaccine.